ETST Shareholders Approve Reverse Split Path and Series B Retirement
Summary
ETST's annual meeting approved a reverse stock split for potential uplisting and authorized the Board to negotiate retirement of the CEO's super-voting Series B Preferred Stock.
Key Events · Corporate Governance and Compliance · ETST
-
Reverse Split Authorized for Uplisting
Shareholders approved pursuing a reverse stock split, valid for 12 months, to be used only if the Board deems it necessary to meet minimum bid price requirements for a national securities exchange listing. Vote: 247,674,256 FOR vs 3,924,655 AGAINST.
-
Series B Preferred Retirement Approved
Shareholders authorized the Board's independent Special Committee to negotiate retirement of the Series B Preferred Stock, which would eliminate the dual-class super-voting control structure. Vote: 115,345,214 FOR vs 316,580 AGAINST, with 125,134,051 abstentions.
-
All Seven Directors Re-elected
All seven director nominees were re-elected, each receiving over 240 million votes except Yovan Sanchez, who received 178,435,892 votes.
-
Say-on-Pay and Auditor Ratified
Shareholders approved the non-dilutive, cash-only executive compensation structure and elected a three-year review cycle for future Say-on-Pay votes. Semple, Marchal & Cooper, LLP was ratified as independent auditor for FY ending March 31, 2027.
Analysis · ETST · Life Sciences
Shareholders approved two pivotal governance changes: a reverse stock split to enable an uplisting to a national exchange, and the retirement of the Series B Preferred Stock that currently gives the CEO super-voting control. The reverse split authorization is valid for 12 months and will only be used if the Board deems it necessary to meet minimum bid price requirements. Retiring the Series B shares would eliminate the dual-class structure and align voting power with economic ownership. Both measures passed with strong support, though the Series B retirement saw 125.1 million abstentions — a signal that some holders are uncertain about the terms of any buyout of the super-voting shares.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETST was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.8M. The 52-week trading range was $0.00 to $0.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.